Showing 1661-1670 of 2526 results for "".
- Visionix USA to Debut VX 40 Couture Auto Lensmeter at Vision Expo Westhttps://modernod.com/news/visionix-usa-to-debut-vx-40-couture-auto-lensmeter-at-vision-expo-west/2484141/Visionix USA will unveil its latest innovation—the VX 40 Couture—at Vision Expo West, September 18–21 at the Venetian Expo Center in Las Vegas. According to Visionix, the VX 40 Couture is a next-
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Bascom Palmer Eye Institute Tops U.S. News & World Report Rankings for 24th Year in a Rowhttps://modernod.com/news/bascom-palmer-eye-institute-tops-us-news-world-report-rankings-for-24th-year-in-a-row/2482911/For the 24th year, Bascom Palmer Eye Institute has been ranked the No. 1 ophthalmology hospital in the United States, according to the newly released 2025 U.S. News & World Report "Best Hospitals" rankings. This marks the 22nd consecutive year th
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- ViaLase Announces Strategic Leadership Transitionshttps://modernod.com/news/vialase-announces-strategic-leadership-transitions/2482876/ViaLase announced changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to
- Beacon Therapeutics Completes Enrollment in Registrational Phase 2/3 VISTA Trial of laru-zova for Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp-1/2482875/Beacon Therapeutics announced it has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). The study enrolled eligible male patients aged 12 to 50 across sites in North America, the United Kingdom